Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JNJ 40929837 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Treatment A: JNJ 40929837 | EXPERIMENTAL | - |
| Treatment B: Placebo | PLACEBO_COMPARATOR | - |
| Treatment C: Montelukast | OTHER | - |
| Name | Type | Description |
|---|---|---|
| JNJ 40929837 | DRUG | On Day 1: participants will receive 2 tablets of 50 mg JNJ 40929837 in the morning and 1 placebo capsule in the evening; from Days 2 to 6: they will receive 1 tablet of 50 mg JNJ 40929837 in the morning and 1 JNJ 40929837 50 mg tablet + 1 placebo capsule in the evening; and on Day 7: 1 tablet of 50 mg JNJ 40929837 in the morning. |
| Placebo | DRUG | On Day 1: participants will receive 2 placebo tablets in the morning and 1 placebo capsule in the evening; from Days 2 to 6: they will receive 1 placebo tablet in the morning and 1 placebo tablet + 1 placebo capsule in the evening; and on Day 7: 1 placebo tablet in the morning. |
| Montelukast | DRUG | On Day 1: participants will receive 2 placebo tablets in the morning and 1 montelukast capsule in the evening; from Days 2 to 6: they will receive 1 placebo tablet in the morning and 1 montelukast capsule + 1 placebo tablet in the evening; and on Day 7: 1 placebo tablet in the morning. |
Inclusion Criteria: - Generally healthy - Have mild atopic asthma requiring no other treatment besides occasional short-acting beta-2-agonists - Have allergen-induced early asthmatic response of at least a 20 percent reduction in forced expiratory volume in 1 second (FEV1) and late asthmatic respons...
JNJ 40929837 is an investigational small molecule being studied for the treatment of asthma. It was evaluated in a Phase 2 clinical trial using a bronchial allergen challenge model to assess its effectiveness in patients with asthma. The drug is not approved and remains in clinical development.
JNJ 40929837 is being developed by Johnson & Johnson, a company traded on the New York Stock Exchange under the ticker JNJ. The drug is an investigational small molecule in Phase 2 clinical development for the treatment of asthma.
JNJ 40929837 is in Phase 2 clinical development. It has completed one Phase 2 trial, which was a randomized, double-blind, placebo-controlled study. The drug is investigational and has not been approved for any use.
JNJ 40929837 has been studied in one completed Phase 2 clinical trial, identified as NCT01241422. This trial evaluated the drug's effectiveness for asthma using a bronchial allergen challenge model and enrolled 22 participants in Germany and the United Kingdom.
No alternative names for JNJ 40929837 have been disclosed. The drug is identified solely by its development code, JNJ 40929837, and is being studied for asthma. It is an investigational small molecule in Phase 2 development.